annual
gener
meet
develop
countri
vaccin
manufactur
network
dcvmn
kunm
china
gather
around
profession
femalefrom
countri
corpor
manufactur
corpor
partner
local
global
health
organ
meet
aim
tighten
collabor
deepen
understand
enhanc
partnership
contribut
futur
vaccin
develop
manufactur
report
provid
summari
major
point
discuss
throughout
meet
dcvmn
presid
datla
thank
institut
medic
biolog
chines
academi
medic
scienc
host
event
welcom
repres
unicef
paho
path
cepi
chai
gavi
ivi
ghif
avaref
nibsc
intravacc
imperi
colleg
london
bmgf
join
network
bring
total
corpor
member
six
vaccin
five
member
compani
receiv
prequalif
pq
member
endors
fiveyear
strategi
strengthen
capabl
produc
sustain
suppli
vaccin
c
lou
scienc
technolog
depart
xu
yunnan
health
commiss
j
ju
medic
product
administr
yunnan
provinc
encourag
expert
entrepreneur
advanc
industri
technolog
system
promot
intern
certif
vaccin
establish
product
suppli
base
meet
intern
standard
work
togeth
intern
organ
nation
health
administr
vaccin
manufactur
strengthen
partnership
health
simao
note
life
expect
extend
year
last
decad
howev
health
inequ
persist
within
countri
challeng
expand
industri
countri
new
strategi
aim
address
inequ
ensur
higher
healthcar
coverag
prevent
emerg
promot
better
health
three
billion
peopl
age
octob
ebola
cholera
yellow
fever
yf
mening
outbreak
nine
countri
vaccin
address
health
emerg
howev
nation
regulatori
author
nra
global
perform
core
regulatori
function
provid
effici
oversight
registr
includ
assess
qualiti
control
postmarket
surveil
vaccin
lead
delay
access
prevent
emerg
situat
thu
need
reli
intern
mechan
product
regul
includ
collabor
registr
procedur
crp
oswald
bmgf
interview
bill
gate
record
video
reflect
achiev
first
decad
vaccin
sinc
annual
child
mortal
decreas
million
around
million
current
save
children
live
noth
phenomen
vaccin
said
mr
gate
context
ensur
simpl
procur
practic
guarante
suppli
avoid
fragment
work
polici
technic
advic
countri
well
stockpil
help
drive
global
region
vaccin
uptak
increas
access
vaccin
everyon
gener
redund
manufactur
need
ensur
economi
scale
sustain
global
suppli
capac
one
factori
goe
offlin
commend
dcvmn
compani
explor
stateoftheart
manufactur
technolog
state
bmgf
commit
strong
dialogu
will
share
risk
make
differ
global
health
mr
gate
conclud
look
forward
partnership
next
decad
davi
path
explain
path
extens
vaccin
innov
access
capabl
support
manufactur
partner
endtoend
partnership
lead
identif
preclin
studi
process
develop
clinic
trial
registr
prequalif
introduct
global
access
effort
exampl
includ
partnership
serum
institut
india
sii
menafrivac
bharat
biotech
rotaviru
cdibp
japanes
enceph
je
beij
biotech
institut
oral
polio
vaccin
opv
achiev
pq
suppli
global
market
path
reli
partnership
industri
research
institut
foundat
regul
success
base
experi
trust
e
kadilli
unicef
highlight
signific
progress
reduc
child
mortal
past
year
immun
key
contributor
achiev
facilit
strong
partnership
includ
vaccin
manufactur
across
four
stream
work
procur
market
shape
suppli
plan
coordin
countri
support
sustain
strengthen
countri
ownership
longterm
immun
sustain
fund
eg
gavi
cofinanc
howev
achiev
sustain
develop
goal
target
child
mortal
requir
innov
includ
programmat
intellig
understand
barrier
deepen
insight
leverag
partnership
privat
sector
increas
immun
rate
fig
j
chu
chai
led
discuss
enhanc
partnership
acceler
vaccin
innov
illustr
live
could
save
improv
success
develop
innov
vaccin
fig
zuma
biomanguinho
describ
three
success
factor
technolog
transfer
initi
introduc
new
vaccin
innov
throughout
transfer
process
establish
manufactur
new
locat
mutual
trust
partner
share
develop
inform
product
capac
industri
expertis
capabl
innov
support
environ
includ
larg
public
market
govern
purchas
power
davi
path
ad
innov
also
includ
packag
distribut
tool
address
nextgener
technolog
transfer
busi
model
stress
manufactur
need
incent
innov
even
opensourc
intellectu
properti
approach
tier
price
model
simao
comment
collabor
achiev
pq
partnership
help
encourag
innov
p
tippoo
share
biovac
engag
path
bmgf
toward
build
vaccin
develop
manufactur
capac
south
africa
highlight
build
partnership
take
time
explain
took
three
year
launch
develop
novel
group
b
streptococcu
vaccin
access
train
expert
allow
project
ramp
quickli
h
iyer
bmgf
highlight
key
challeng
manufactur
assess
potenti
new
vaccin
futur
challeng
includ
mrna
vaccin
biomark
adapt
clinic
trial
design
human
challeng
model
infect
panelist
encourag
manufactur
leverag
innov
capabl
partnership
e
baker
gavi
discuss
major
global
vaccin
market
trend
estim
chang
impact
vaccin
financ
procur
method
fig
becom
increasingli
challeng
global
actor
oper
environ
due
chang
sourc
financ
increas
cost
immun
program
also
due
uncertainti
around
procur
channel
see
also
fig
legend
b
giers
remark
gavi
financ
play
big
role
access
tradit
newer
vaccin
financ
crucial
import
vaccin
lack
dual
market
public
privat
market
develop
industri
market
howev
gavi
countri
develop
selffinanc
capac
lower
rate
vaccin
uptak
observ
past
address
new
procur
mechan
ottosen
unicef
mention
innov
procur
approach
shift
multiyear
tender
contract
pneumococc
conjug
vaccin
pcv
multiphas
tender
implement
follow
consult
industri
aim
achiev
vaccin
secur
includ
divers
supplier
base
unicef
procur
consid
price
also
factor
contribut
ensur
sustain
market
access
vaccin
immun
programm
j
fitzsimmon
paho
revolv
fund
comment
collabor
approach
share
demand
forecast
vaccin
region
epidem
illustr
elimin
yellow
fever
epidem
eye
initi
intern
coordin
group
vaccin
provis
mechan
facilit
access
addit
suppli
yf
vaccin
procur
constrain
global
suppli
situat
hein
gavi
emphas
global
vaccin
market
valu
doubl
last
decad
innov
vaccin
attract
price
high
incom
countri
hic
howev
valu
tradit
vaccin
stagnat
outbreak
vaccin
lack
market
hic
manufactur
oper
segment
face
volatil
unpredict
besid
regulatori
fragment
gavi
approach
aggreg
longterm
visibl
financ
r
iqbal
bmgf
reflect
suppli
factor
shape
global
bmgf
invest
vaccin
ensur
adequ
suppli
base
align
gavi
principl
healthi
market
minim
shortag
risk
increas
market
share
among
manufactur
foster
multipl
suppli
option
bmgf
also
invest
manufactur
technolog
platform
reduc
product
cost
g
rockman
ghif
introduc
exampl
capit
sourc
develop
new
vaccin
note
differ
fund
nt
need
repay
financ
seek
financi
return
outlin
profil
cepi
bmgfsif
ghif
fund
tabl
open
discuss
note
ghif
scale
effort
financ
global
health
technolog
new
sourc
capit
rebrand
adjuv
f
kristensen
cepi
provid
overview
coalit
develop
vaccin
prioriti
pathogen
middl
east
respiratori
syndrom
mer
lassa
nipah
virus
platform
rapid
vaccin
develop
new
threat
cepi
mission
enabl
equit
access
vaccin
affect
popul
outbreak
funder
facilit
improv
prepared
respons
sustain
j
yip
bmgf
share
featur
sif
guarante
loan
fund
invest
equiti
invest
addit
core
grant
contract
manufactur
r
product
improv
sif
invest
focu
infecti
diseas
affect
disadvantag
popul
sinc
sif
invest
us
billion
compani
academ
laboratori
foster
product
develop
deliveri
datla
biolog
e
comment
r
fund
financ
chang
last
decad
india
previous
ventur
capit
vaccin
grant
critic
grant
fund
missionori
restrict
financi
object
usual
lead
access
agreement
lower
price
specif
fig
illustr
global
immun
target
set
unicef
global
stakehold
reduc
child
mortal
achiev
base
exampl
desir
outcom
unicef
shift
approach
also
engag
prelicensur
includ
privat
sector
execut
level
advoc
requir
invest
meet
futur
need
children
adolesc
consid
entir
ecosystem
rel
level
difficulti
achiev
target
reflect
axi
time
achiev
shown
x
axi
size
bubbl
denot
potenti
impact
goalstarget
achiev
access
afford
pcv
middl
incom
countri
may
next
high
impact
achiev
size
bubbl
denot
potenti
impact
goalstarget
achiev
volum
time
window
privat
equiti
requir
cycl
therefor
ideal
vaccin
prasad
bharat
biotech
state
one
signific
grant
help
advanc
manufactur
rotaviru
vaccin
invest
base
predict
howev
often
difficult
measur
financi
success
paramet
lead
unpredict
rate
return
invest
vaccin
without
longterm
suppli
contract
v
pavliak
ivi
invit
expert
comment
innov
foster
vaccin
afford
robinson
bmgf
comment
innov
simplifi
process
translat
capit
save
product
cost
develop
world
recent
found
gate
medic
research
institut
gmri
take
small
biotech
approach
innov
drug
diagnost
vaccin
transfer
manufactur
focus
diseas
affect
develop
world
priorit
tb
hiv
malaria
r
shattock
imperi
colleg
london
note
industri
typic
final
manufactur
process
conduct
clinic
trial
expens
time
consum
trial
requir
fix
manufactur
process
appli
adapt
clinic
trial
design
offer
promis
altern
dat
ad
vabiotech
transfer
oral
cholera
vaccin
ocv
technolog
ivi
develop
highqual
vaccin
clinic
trial
variou
popul
optim
manufactur
technolog
expand
manufactur
capac
transfer
interest
manufactur
tomar
cadila
biolog
explain
effici
lowcost
manufactur
must
ensur
enough
product
capac
achiev
economi
scale
procur
system
influenc
manufactur
process
thu
critic
engag
appropri
stakehold
increas
awar
ensur
market
new
product
cadila
licens
new
rabi
vaccin
thank
success
partnership
r
suri
panacea
ad
afford
vaccin
requir
longerterm
approach
consid
sustain
manufactur
cost
innov
exampl
process
chang
inactiv
polio
vaccin
ipv
reduc
cost
tenfold
panelist
conclud
manufactur
add
valu
futur
vaccin
robinson
bmgf
illustr
innov
support
proofofconcept
studi
univercel
modular
manufactur
platform
vaccin
antibodi
protein
low
capit
cost
platform
facilit
engag
region
local
manufactur
gmri
also
address
proofofconcept
studi
develop
new
diagnost
drug
bioproduct
furthermor
welltrain
workforc
ensur
high
qualiti
top
prioriti
manufactur
r
suri
panacea
summar
tenyear
effort
bring
fulli
liquid
wp
ipvbas
hexaval
vaccin
market
prove
safeti
toler
openlabel
random
multicent
studi
show
noninferior
seroprotect
infant
achiev
broad
longterm
protect
compar
licens
combin
vaccin
vaccin
approv
indian
nra
r
dhere
sii
mention
thermost
acywx
mening
vaccin
suitabl
prevent
futur
outbreak
despit
signific
drop
mening
type
case
vaccin
sinc
increas
case
relat
serogroup
cywx
observ
africa
thu
polysaccharid
conjug
serogroupspecif
cell
bank
develop
uniform
highyield
growth
kinet
safeti
immunogen
acywx
vaccin
confirm
efficaci
studi
start
aim
pq
preliminari
studi
add
serotyp
b
start
yang
walvax
reveal
immunogen
safeti
profil
pcv
infant
random
doubleblind
control
clinic
studi
demonstr
noninferior
compar
prevnar
licens
vaccin
china
vaccin
like
licens
lottolot
consist
noninferior
studi
compar
prevnar
licens
china
last
year
l
du
zhifei
describ
develop
vaccin
shigella
second
lead
caus
diarrhea
worldwid
caus
million
death
annual
bival
shigella
conjug
vaccin
candid
develop
use
opolysaccharid
lp
conjug
carrier
protein
two
strain
shigella
flexneri
plesiomona
shigelloid
earli
studi
healthi
subject
identifi
dosag
immun
schedul
underway
che
imbcam
present
new
live
attenu
mump
vaccin
address
reemerg
outbreak
relat
f
genotyp
sp
viral
strain
viru
shed
studi
indic
favor
safeti
immunogen
profil
phase
ii
trial
demonstr
noninferior
seroconvers
neutral
hemagglutinationinhibit
antibodi
signific
increas
cellular
immun
efficaci
studi
follow
c
kirkwood
bmgf
acknowledg
rotaviru
vaccinesdriven
improv
child
health
highlight
effort
toward
improv
vaccin
perform
deliveri
despit
good
safeti
profil
four
pq
live
attenu
oral
rotaviru
vaccin
million
children
worldwid
still
lack
access
intussuscept
lower
efficaci
remain
concern
countri
biofarma
develop
strain
oral
vaccin
schedul
show
excel
protect
rotaviru
gastroenter
inject
nonrepl
vaccin
may
improv
safeti
efficaci
could
use
combin
vaccin
two
candid
develop
trival
nonrepl
rotaviru
vaccin
express
e
coli
develop
path
sk
bioscienc
partnershow
good
safeti
immunogen
eg
neutral
antibodi
human
clinic
studi
clinic
protect
evalu
inactiv
wholeviru
particl
rotaviru
vaccin
develop
us
cdc
sii
partner
show
protect
immun
anim
kumar
zydu
cadila
introduc
novel
monoclon
antibodi
mab
cocktail
postbit
prophylaxi
rabi
infect
rabi
viru
progress
peripher
tissu
spinal
cord
caus
brain
inflamm
fatal
paralysi
immedi
wound
wash
follow
rabi
vaccin
antirabiesimmunoglobulin
rig
neutral
viru
protect
diseas
rabimab
cocktail
two
serumfre
antig
protein
monoclon
antibodi
neutral
virus
isol
mani
countri
anim
clinic
data
random
multicentr
open
label
comparatorcontrol
studi
demonstr
safeti
toler
efficaci
coadminist
rabi
vaccin
vaxirab
n
indic
noninferior
imogam
missailidi
biomanguinho
describ
new
yf
vaccin
product
process
aim
doubl
capac
develop
purifi
yf
vaccin
made
viru
strain
vero
cell
cultur
inactiv
bpropiolacton
product
capac
latter
increas
scaleup
process
optim
ge
healthcar
technolog
antibioticfre
formul
improv
qualiti
furthermor
biomanguinho
initi
three
parallel
zika
vaccin
project
allow
compar
clinic
trial
verocel
inactiv
viru
vaccin
pregnant
women
epidem
attenu
vaccin
recombin
chimer
viru
yf
strain
express
zika
viru
protein
immunogen
neurovirul
nonhuman
primat
studi
w
meng
sinovac
share
clinic
develop
sabin
ipv
sipv
facilit
two
product
design
pure
sipv
alumadjuv
sipv
multidos
vial
phase
clinic
studi
show
seroconvers
rate
high
gmt
valu
proport
antigen
dosag
noninferior
phase
studi
compar
sabin
ipv
salk
ipv
underway
aim
pq
approv
j
shih
innovax
discuss
hepat
e
cervic
cancer
vaccin
hepat
e
outbreak
africa
southeast
asia
show
seriou
risk
pregnant
women
vaccin
produc
e
coli
genotyp
show
cross
protect
genotyp
approv
china
pakistan
phase
trial
plan
unit
state
bival
vaccin
target
femal
also
produc
e
coli
show
safeti
efficaci
clinic
studi
compar
similar
bival
quadrival
hpv
vaccin
studi
adolesc
girl
schedul
show
compar
immunogen
dose
vaccin
plan
precioso
butantan
report
secondgener
recombin
dengu
vaccin
dengu
caus
antigen
distinct
serotyp
endem
countri
report
circul
four
serotyp
infect
one
serotyp
confer
lifelong
immun
serotyp
homotyp
protect
cross
immun
serotyp
heterotyp
protect
persist
one
two
year
sever
dengu
case
observ
secondari
heterotyp
infect
antibodydepend
enhanc
live
attenu
lyophil
vaccin
fig
safe
immunogen
well
toler
undergo
random
multicentr
doubleblind
placebocontrol
phase
iii
trial
brazil
one
dose
given
subcutan
subject
year
old
vaccin
antigen
expect
confer
least
protect
symptomat
diseas
previou
dengu
exposur
associ
advers
reaction
u
rosskopf
introduc
global
whonat
control
laboratori
ncl
network
biolog
establish
respons
nrasncl
provid
rigor
oversight
vaccin
test
thousand
vaccin
lot
approv
specif
network
promot
exchang
technic
inform
predominantli
test
pq
vaccin
effici
use
resourc
mutual
recognit
lot
releas
therebi
reduc
cost
minim
risk
inaccur
result
foster
principl
share
electron
platform
creat
network
member
exchang
qualiti
technic
inform
confidenti
set
network
compris
ncl
vaccineproduc
countri
test
laboratori
nrasncl
countri
receiv
unprocur
vaccin
also
nonprequalifi
vaccin
un
agenc
manufactur
associ
stakehold
principl
replac
refin
reduct
anim
research
europeanl
initi
provid
intern
recogn
framework
ethic
anim
use
test
principl
encourag
altern
anim
test
use
anim
avoid
aim
reduc
use
improv
anim
welfar
inform
see
http
feaver
nibsc
discuss
vaccin
test
use
new
method
develop
vaccin
life
cycl
exemplifi
nibsc
mening
group
work
manufactur
assur
vaccin
batch
qualiti
introduc
vitro
test
measur
presenc
pyrogen
therebi
reduc
use
anim
anoth
exampl
histamin
sensit
test
acellular
pertussi
vaccin
evalu
cho
cell
intox
cluster
assay
collabor
studi
third
exampl
evalu
deep
sequenc
ds
altern
maprec
polio
vaccin
manufactur
intern
collabor
studi
particip
ncl
vaccin
manufactur
assess
consist
opv
sabin
polioviru
type
show
good
correl
maprec
ds
studi
build
databas
mutat
composit
seed
virus
vaccin
batch
differ
manufactur
new
approach
could
appli
licens
vaccin
boyl
n
agarw
path
express
need
highqual
antibodi
test
character
pcv
r
manufactur
process
collabor
manufactur
hybridoma
gener
screen
qualiti
eg
absenc
crossreact
bind
affin
set
afford
mab
commerci
avail
second
set
mab
follow
solut
present
global
access
commerci
sustain
repositori
highqual
afford
mab
common
pneumococc
serotyp
g
kersten
intravacc
propos
test
scheme
dtp
basedvaccin
reduc
use
anim
manufactur
serolog
altern
cell
cultur
immunephysicochem
method
potenc
test
toxoid
vaccin
base
lethal
challeng
anim
although
new
method
tetanu
diphtheria
receiv
regulatori
accept
altern
serolog
potenc
test
pertussi
vaccin
propos
use
conjunct
thelper
cell
respons
qualit
assay
altern
elisa
quantifi
key
antigen
wp
vaccin
could
use
next
serolog
assay
consist
approach
support
regulatori
accept
studi
outlin
consider
stakehold
boyl
bmgf
k
mahmood
path
jointli
present
establish
intern
refer
reagent
sipv
expert
vaccin
manufactur
discuss
assay
measur
dantigen
content
sipv
product
harmon
potenc
test
nibsc
assess
suitabl
intern
standard
convent
ipv
cipv
measur
sipv
product
collabor
studi
includ
product
sever
manufactur
despit
good
perform
cipv
consid
unsuit
sipv
assay
valid
interlaboratori
variabl
inhous
method
improv
use
sipv
sampl
refer
second
collabor
studi
confirm
dantigen
measur
sipv
improv
use
sipv
sampl
refer
base
character
stabil
data
first
sipv
endors
expert
committe
biolog
standard
octob
avail
nibsc
use
potenc
test
e
cook
introduc
regulatori
activ
focus
crp
acceler
registr
emerg
countri
crp
base
principl
cooper
relianc
harmon
voluntari
inform
share
avoid
duplic
effort
enabl
faster
effici
access
qualiti
vaccin
respect
sovereignti
nation
decisionmak
thu
far
countri
accept
crp
sinc
crp
enabl
registr
medicin
within
averag
day
implement
principl
contribut
achiev
vaccin
registr
pentaval
regist
ethiopia
within
month
cholera
vaccin
regist
nigeria
caribbean
countri
month
still
need
optim
crp
vaccin
better
defin
prioriti
vaccin
prioriti
countri
whoafro
explain
impact
joint
scientif
ethic
review
clinic
trial
applic
africa
grow
public
health
need
requir
faster
access
qualityassur
medic
product
avaref
facilit
develop
tabl
compar
overview
cepi
bmgfsif
ghif
fund
assess
across
six
aspect
list
first
column
includ
fund
natur
target
product
focu
area
typic
valu
rang
fund
fund
structur
earlyl
phase
develop
fund
tabl
courtesi
foster
nra
converg
harmon
procedur
countri
requir
agreement
manufactur
andor
sponsor
well
agreement
target
countri
nra
ec
follow
whoavaref
guidanc
h
langar
whoemro
describ
crpfacilit
registr
polio
vaccin
joint
dossier
review
eastern
mediterranean
region
emr
countri
recommend
introduct
ipv
ensur
least
two
avail
brand
ipv
regist
emr
countri
two
countri
lack
regist
ipv
five
countri
one
regist
ipv
brand
joint
registr
procedur
legal
accept
countri
issuanc
market
author
commit
test
site
inspect
grant
joint
evalu
meet
focus
ipv
vaccin
dossier
submit
nra
conduct
octob
particip
nra
report
respect
registr
committe
final
decis
five
countri
regist
ipv
notabl
particip
manufactur
meet
acceler
process
address
question
concern
express
nra
n
dellepian
dcvmn
discuss
possibl
improv
vaccin
registr
procedur
emerg
countri
address
previous
identifi
challeng
joint
industri
regulatori
expert
work
group
develop
four
propos
streamlin
procedur
align
dossier
first
registr
procedur
could
reli
pq
certif
appli
crp
dossier
evalu
could
reli
batch
releas
data
test
inspect
alreadi
conduct
registr
procedur
nonpq
vaccin
could
reli
dossier
data
provid
manufactur
countri
nra
mutual
recognit
agreement
base
releas
test
conduct
whocontract
laboratori
see
u
rosskopf
second
align
dossier
number
system
across
countri
region
could
improv
follow
ich
ctd
eu
notic
applic
also
recogn
third
use
applic
form
templat
propos
tabular
format
maintain
three
key
section
main
subhead
fourth
consid
presubmiss
meet
applic
regul
postmarket
pharmacovigil
system
improv
registr
procedur
dr
dellepian
conclud
regulatori
converg
practic
improv
registr
access
vaccin
global
b
giers
introduc
two
new
multistakehold
initi
improv
vaccin
deliveri
total
system
effect
tse
framework
assist
decisionmak
identifi
select
vaccin
product
accord
attribut
best
meet
need
vaccin
innov
prioritis
strategi
vip
aim
priorit
deliveri
technolog
identifi
product
attribut
clarifi
manufactur
stakehold
regard
invest
decis
tse
vip
assum
differenti
deliveri
approach
need
given
unvaccin
popul
live
cluster
area
locat
key
countri
fig
focus
poor
vulner
popul
exampl
innov
includ
heatstablefreezest
formul
label
track
temperatur
exposur
jetinjector
powderinhal
nebul
devic
compact
prefil
autodis
devicessyring
blowfills
contain
integr
reconstitut
devic
microarray
patch
control
temperatur
chain
use
vaccin
kristensen
path
moder
discuss
innov
technolog
tse
vip
help
countri
enhanc
coverag
equiti
suitabl
vaccin
specif
need
r
park
eubiolog
mention
chang
ocv
vial
present
glass
plastic
reduc
storag
volumecold
chain
footprint
cost
good
also
facilit
vaccin
administr
field
worker
therebi
increas
ocv
coverag
achiev
set
goal
v
hsu
bmgf
explain
bmgf
see
commun
need
prioriti
invest
decis
support
ocv
product
innov
driven
polici
expand
ocv
stockpil
dose
million
dose
save
mani
live
r
kapoor
nation
univers
singapor
note
tse
framework
guid
lmic
identifi
criteria
product
select
mic
tse
bring
differ
group
togeth
better
inform
decisionmak
process
improv
transpar
enabl
comparison
differ
vaccin
diseas
eg
rotarix
rotateq
besid
comparison
vaccin
across
diseas
framework
inform
countri
cost
feasibl
packag
schedul
etc
help
manufactur
understand
basi
decisionmak
need
hein
gavi
confirm
vip
tse
help
gavi
drive
vaccin
innov
meet
countri
need
support
immun
coverag
equiti
process
provid
align
perspect
greater
clariti
manufactur
make
inform
invest
decis
jadhav
sii
state
may
costli
manufactur
developproduc
mani
product
variat
driven
tse
vip
therefor
uniform
base
prefer
product
profil
defin
need
ad
introduct
new
technolog
coexist
alreadi
establish
technolog
time
global
partner
dcvmn
supplier
agre
stabl
vaccin
suppli
need
industri
understand
demand
market
evolut
help
guid
invest
decis
progress
toward
secur
futur
vaccin
suppli
momeni
unicef
provid
updat
fig
around
countri
suppli
billion
dose
vaccin
unicef
valu
us
billion
reach
children
year
age
eleven
dcvmn
compani
suppli
billion
dose
tradit
vaccin
valu
us
million
suppli
crise
earli
unicef
experienc
sever
vaccin
shortag
due
merger
acquisit
exit
unicef
market
highlight
import
longerterm
forecast
manufactur
plan
secur
access
suppli
current
unicef
experienc
insuffici
suppli
rotaviru
ipv
hpv
reli
limit
supplier
base
pcv
typhoid
je
vaccin
unicef
process
implement
sustain
procur
approach
requir
manufactur
polici
encourag
innov
reduc
carbon
footprint
wast
dispos
n
steensma
chai
offer
support
compani
help
develop
busi
strategi
includ
build
busi
case
enter
market
gather
market
intellig
light
gavi
transit
countri
becom
middl
incom
countri
mic
respons
request
dcvm
manufactur
chai
increas
support
provid
market
intellig
mic
r
suri
panacea
highlight
trust
transpar
fair
key
characterist
deal
unicef
mani
year
request
better
demand
visibl
includ
chang
relat
vaccin
campaign
improv
multiphas
tender
led
market
exit
pentaval
could
consid
consensu
among
manufactur
challeng
negoti
contractu
term
outsid
unicef
standard
contractu
arrang
l
yang
cnbg
appreci
collabor
unicef
process
forecast
includ
proactiv
problemsolv
lead
becom
supplier
request
aggreg
forecast
across
unicef
selfprocur
countri
support
work
govern
even
demand
spike
highlight
great
potenti
chines
supplier
regist
vaccin
manufactur
l
shi
walvax
said
compani
commit
achiev
pq
ensur
product
meet
intern
standard
walvax
highlight
concern
regard
countri
product
prefer
lack
prefer
panel
agre
prequalif
import
intern
label
qualiti
assur
complianc
irrespect
countri
product
particip
also
discuss
challeng
surround
countri
product
prefer
registr
requir
conflict
prioriti
especi
product
newli
prequalifi
countri
program
drive
earlier
access
despit
increas
complex
legisl
regulatori
requir
close
lectur
conclud
remark
c
nannei
goldin
deliv
close
lectur
focus
progress
challeng
sustain
influenza
vaccin
product
ensur
pandem
prepared
holist
approach
prepared
includ
surveil
evidencebas
polici
strategi
deploy
influenza
vaccin
suffici
vaccin
suppli
consider
rapid
deploy
vaccin
emerg
includ
regulatori
capac
distribut
system
monitor
system
healthcar
worker
familiar
influenza
immun
vaccin
polici
target
group
commun
strategi
global
season
influenza
vaccin
manufactur
capac
tripl
million
dose
billion
dose
period
estim
global
pandem
influenza
product
capac
grew
billion
billion
potenti
dose
develop
new
global
influenza
strategi
launch
earli
highlight
need
sustain
local
product
influenza
vaccin
dcvmn
key
partner
global
influenza
prepared
respons
activ
advoc
sustain
vaccin
product
capac
develop
countri
present
discuss
throughout
meet
demonstr
progress
achiev
made
possibl
intern
cooper
highlight
import
partnership
foster
innov
public
health
particularli
develop
countri
year
support
bill
melinda
gate
foundat
path
partner
unlock
economi
scale
sustain
vaccin
suppli
capac
develop
countri
exemplifi
partnership
menafrivac
rotaviru
japanes
enceph
new
polio
vaccin
achiev
pq
suppli
global
market
pool
procurementfinanc
mechan
util
paho
revolv
fund
unicef
gavi
partnership
countri
help
protect
peopl
known
emerg
infecti
diseas
partnership
enhanc
influenza
vaccin
manufactur
capac
therebi
increas
pandem
influenza
prepared
endur
partnership
basi
innov
strengthen
industri
develop
countri
come
decad
manufactur
partner
take
pride
collect
work
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
